MCID: INT079
MIFTS: 51

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 52 6 15 17 71
Cholangiocarcinoma 43 71
Peripheral Intrahepatic Cholangiocarcinoma 71
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
MeSH 43 D018281
NCIt 49 C35417
SNOMED-CT 67 109842005
ICD10 32 C22.1
UMLS 71 C0206698 C0345905 C3273048

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 52 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice , abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to mucinous intrahepatic cholangiocarcinoma and sarcomatous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CCAT1 (Colon Cancer Associated Transcript 1), and among its related pathways/superpathways are mTOR signaling pathway (KEGG) and Central carbon metabolism in cancer. The drugs Celecoxib and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 750)
# Related Disease Score Top Affiliating Genes
1 mucinous intrahepatic cholangiocarcinoma 35.0 KRT7 IDH1
2 sarcomatous intrahepatic cholangiocarcinoma 34.9 KRT7 KRT19 AFP
3 klatskin's tumor 33.5 KRT7 KRT19 APC AFP
4 cholangiocarcinoma 33.2 TUG1 TP53 RASGEF1A MUC4 KRT7 KRT19
5 adenocarcinoma 31.7 TP53 MUC4 KRT7 KRAS FGFR2 APC
6 adenoma 31.4 TP53 KRT7 KRAS APC
7 hemangioma 31.4 TP53 KRT7 KRAS IDH1
8 cholangitis, primary sclerosing 31.3 KRT7 KRT19 AFP
9 bile duct cysts 31.3 KRT7 KRT19 KRAS AFP
10 papillary adenocarcinoma 31.2 TP53 KRT7 KRT19 KRAS
11 pancreatic ductal adenocarcinoma 31.2 TP53 MUC4 KRT19 KRAS
12 colorectal adenocarcinoma 31.1 TP53 KRT7 KRAS APC
13 signet ring cell adenocarcinoma 31.1 TP53 KRT7 KRAS
14 cavernous hemangioma 31.0 KRT7 KRT19 AFP
15 pancreatic adenocarcinoma 30.9 TP53 MUC4 KRT19 KRAS FGFR2 APC
16 angiosarcoma 30.9 TP53 KRT7 KRAS
17 adenofibroma 30.9 TP53 KRT7 KRT19
18 intrahepatic bile duct adenoma 30.9 KRT7 KRT19 AFP
19 bile duct cystadenocarcinoma 30.9 KRT7 AFP
20 thyroid tumor 30.9 TP53 KRAS FGFR2
21 rectum adenocarcinoma 30.9 TP53 KRT7 KRAS
22 appendix adenocarcinoma 30.8 KRT7 KRAS
23 mucinous adenocarcinoma 30.8 TP53 KRT7 KRT19 KRAS
24 carcinosarcoma 30.8 TP53 KRT7 KRAS
25 benign mesothelioma 30.7 KRT7 AFP
26 adenosquamous carcinoma 30.7 TP53 MUC4 KRT7 KRT19 KRAS
27 bile duct cancer 30.7 TP53 MUC4 MIR424 KRT7 KRT19 KRAS
28 fibrolamellar carcinoma 30.7 KRT7 KRT19 FGFR2 AFP
29 thyroid gland cancer 30.6 TP53 KRT7 KRT19 KRAS APC
30 ampulla of vater cancer 30.6 TP53 KRT7 KRAS
31 biliary tract benign neoplasm 30.6 TP53 KRT7 KRT19 KRAS AFP
32 hepatoblastoma 30.5 TUG1 TP53 KRT7 APC AFP
33 squamous cell carcinoma 30.5 TUG1 TP53 KRT7 KRT19 FGFR2 CCAT2
34 intrahepatic biliary papillomatosis 30.5 KRAS AFP
35 villous adenoma 30.5 TP53 KRAS APC
36 transverse colon cancer 30.5 KRT7 KRAS
37 wilms tumor 1 30.4 TP53 KRT7 KRAS AFP
38 bronchiolo-alveolar adenocarcinoma 30.4 MUC4 KRT7 KRAS
39 gallbladder cancer 30.4 TUG1 TP53 KRT7 KRT19 KRAS CCAT1
40 small intestine cancer 30.4 TP53 KRT7 KRAS
41 bile duct disease 30.4 TP53 MIR424 KRT7 KRT19 KRAS AFP
42 small cell carcinoma 30.4 TP53 KRT7 KRT19 KRAS
43 dysgerminoma 30.4 KRT7 FGFR2 AFP
44 gastric adenocarcinoma 30.3 TP53 MUC4 KRT7 KRAS IDH1 FGFR2
45 biliary tract disease 30.3 TP53 MIR424 KRT7 KRT19 KRAS AFP
46 gallbladder disease 30.3 TP53 KRT7 KRAS AFP
47 rectum cancer 30.3 MIR424 MIR214 KRAS APC
48 renal cell carcinoma, papillary, 1 30.2 TP53 MIR424 KRT7 KRT19
49 clear cell renal cell carcinoma 30.1 TUG1 TP53 KRT7 KRAS IDH1 CCAT2
50 osteogenic sarcoma 30.0 TUG1 TP53 CCAT2 CCAT1

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.4 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.4 AFP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.4 APC
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.4 AFP APC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.4 APC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.4 AFP
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.4 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.4 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.4 APC
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 9.4 APC
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.4 AFP

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AFP APC FGFR2 IDH2 KRAS KRT19

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Etomidate Approved Phase 4 33125-97-2 36339 667484
5 Anesthetics, Inhalation Phase 4
6 Cyclooxygenase 2 Inhibitors Phase 4
7 Cyclooxygenase Inhibitors Phase 4
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4
9 Platelet Aggregation Inhibitors Phase 4
10
Bismuth Phase 4 7440-69-9 16682734 105143
11 Ulipristal acetate Phase 4 126784-99-4
12 Omega 3 Fatty Acid Phase 4
13 Narcotics Phase 4
14 Hypnotics and Sedatives Phase 4
15 Anesthetics, General Phase 4
16 Analgesics Phase 4
17 Analgesics, Opioid Phase 4
18 Anesthetics, Intravenous Phase 4
19 Anti-Anxiety Agents Phase 4
20 GABA Modulators Phase 4
21
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
22
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
23
nivolumab Approved Phase 3 946414-94-4
24
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
25
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
26
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
27
Ipilimumab Approved Phase 3 477202-00-9
28
Simvastatin Approved Phase 3 79902-63-9 54454
29
Gemcitabine Approved Phase 3 95058-81-4 60750
30
Fluorouracil Approved Phase 3 51-21-8 3385
31
leucovorin Approved Phase 3 58-05-9 6006 143
32
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
33
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
34
Citalopram Approved Phase 3 59729-33-8 2771
35
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37 Hematinics Phase 3
38 Emetics Phase 3
39 Anthelmintics Phase 3
40 Antiparasitic Agents Phase 3
41 Pharmaceutical Solutions Phase 3
42 Calcium, Dietary Phase 2, Phase 3
43 Folfirinox Phase 2, Phase 3
44 Hypolipidemic Agents Phase 3
45 Anticholesteremic Agents Phase 3
46 Lipid Regulating Agents Phase 3
47 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
48 Trace Elements Phase 3
49 Micronutrients Phase 3
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 579)
# Name Status NCT ID Phase Drugs
1 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
2 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
3 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
4 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
5 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
6 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
7 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
8 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
9 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
10 Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent Completed NCT01315522 Phase 4
11 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
13 Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study. Recruiting NCT04378023 Phase 4 Neoadjuvant Chemo-radiotherapy
14 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Recruiting NCT01642875 Phase 4
15 Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
16 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
17 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
18 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial Unknown status NCT00653978 Phase 3
19 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
20 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
21 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
22 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
23 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
24 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
25 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
26 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
27 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
28 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
29 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
30 Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT03771846 Phase 3 irinotecan, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
31 Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency Recruiting NCT03345303 Phase 3 Bortezomib
32 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
33 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
34 A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients Recruiting NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
35 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
36 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
37 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
38 Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
39 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
40 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
41 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 Bintrafusp alfa;Placebo;Gemcitabine;Cisplatin
42 Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC) Recruiting NCT02232490 Phase 3
43 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
44 A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer Recruiting NCT04163900 Phase 3 NUC-1031;Gemcitabine;Cisplatin
45 A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma Recruiting NCT04003636 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
46 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
47 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
48 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
49 Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
50 Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

40
Liver, Lymph Node, T Cells, Pancreas, Colon, Breast, Lung

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 12227)
# Title Authors PMID Year
1
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. 46 61
19755794 2009
2
Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. 61
31852273 2020
3
Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism. 61
32453420 2020
4
Abdominal and gluteofemoral size and risk of liver cancer: The liver cancer pooling project. 61
31677159 2020
5
The Prognostic Impact of Leucine-Rich α-2-Glycoprotein-1 in Cholangiocarcinoma and Its Association With the IL-6/TGF-β1 Axis. 61
32278969 2020
6
Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. 61
31705172 2020
7
ASO Author Reflections: Essential to Reduce Adverse Outcomes in Perihilar Cholangiocarcinoma Surgery-Portal Vein Embolization. 61
32152772 2020
8
Integrin αvβ6 predicts poor prognosis and promotes resistance to cisplatin in hilar cholangiocarcinoma. 61
32534716 2020
9
ASO Author Reflections: Left Trisectionectomy for Bismuth-Corlette Type IV Perihilar Cholangiocarcinoma with Left-Sided Predominance. 61
32323086 2020
10
Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. 61
32171892 2020
11
Hepatic artery infusion pumps. 61
32215927 2020
12
A case of peribiliary hepatic cysts in a cirrhotic liver: A mimicker of Klatskin Tumor. 61
32435324 2020
13
The interplay between thyroid and liver: implications for clinical practice. 61
32166702 2020
14
Progress and prospects of biomarkers in primary liver cancer (Review). 61
32236573 2020
15
Have incidence rates of liver cancer peaked in the United States? 61
32294255 2020
16
Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma. 61
32103419 2020
17
Identification of key genes associated with the progression of intrahepatic cholangiocarcinoma using weighted gene co-expression network analysis. 61
32565973 2020
18
Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives. 61
32344256 2020
19
Predictive role of neutrophil to lymphocyte ratio in patients with intrahepatic cholangiocarcinoma submitted to treatment of 90Y-microspheres. 61
32520895 2020
20
Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. 61
32232655 2020
21
Corrigendum to "Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma" [Eur. J. Radiol. 125 (2020) 108897]. 61
32361382 2020
22
Role of Central Hypo-enhancement in the Hepatic Arterial Phase of Dynamic Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma. 61
32152739 2020
23
Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complications. 61
32035181 2020
24
Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09). 61
32180066 2020
25
Portal Vein Embolization for Perihilar Cholangiocarcinoma: A Story Worth Repeating. 61
32112210 2020
26
Liver Transection-First Approach in Left Trisectionectomy for Perihilar Cholangiocarcinoma. 61
32152773 2020
27
Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. 61
32473757 2020
28
Autophagy Suppression Accelerates Apoptosis Induced by Norcantharidin in Cholangiocarcinoma. 61
31612378 2020
29
Role of noncoding RNAs in cholangiocarcinoma (Review). 61
32319584 2020
30
[Systemic Chemotherapy of gallbladder carcinoma - simply the same as for cholangiocarcinoma?] 61
32544968 2020
31
Diagnostic value of contrast-enhanced ultrasonography for intrahepatic cholangiocarcinoma with tumor diameter larger than 5 cm. 61
31987716 2020
32
Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab. 61
32536644 2020
33
Insufficient future liver remnant and preoperative cholangitis predict perioperative outcome in perihilar cholangiocarcinoma. 61
32546423 2020
34
Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. 61
32564137 2020
35
Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. 61
32268230 2020
36
Asbestos exposure and increased risk of intrahepatic cholangiocarcinoma: enough to infer causality? 61
32569767 2020
37
miR-373 inhibits autophagy and further promotes apoptosis of cholangiocarcinoma cells by targeting ULK1. 61
32125086 2020
38
Identification of exosomal miRNAs as diagnostic biomarkers for cholangiocarcinoma and gallbladder carcinoma. 61
32527999 2020
39
Endoscopic radiofrequency ablation of a cholangiocarcinoma with targeted intraductal cholangioscopic access. 61
32559780 2020
40
Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome. 61
32543919 2020
41
Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study. 61
32118610 2020
42
Unilateral Stent Insertion With High-intensity Focused Ultrasound Ablation for Hilar Cholangiocarcinoma. 61
32168167 2020
43
LINC01410 promotes cell proliferation and migration of cholangiocarcinoma through modulating miR-124-3p/SMAD5 axis. 61
31951299 2020
44
Intrahepatic Cholangiocarcinoma in a Patient with Hepatitis C: A Cautionary Tale. 61
32481777 2020
45
Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. 61
32505533 2020
46
Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy. 61
32506715 2020
47
Should We Reevaluate Liver Transplantation as an Alternative to Resection for the Treatment of Intrahepatic Cholangiocarcinoma? 61
32297472 2020
48
Preoperative Ultrasound Radiomics Signatures for Noninvasive Evaluation of Biological Characteristics of Intrahepatic Cholangiocarcinoma. 61
31494003 2020
49
RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding. 61
31541481 2020
50
A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. 61
32495285 2020

Variations for Intrahepatic Cholangiocarcinoma

ClinVar genetic disease variations for Intrahepatic Cholangiocarcinoma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.8332G>T (p.Ala2778Ser)SNV Conflicting interpretations of pathogenicity 133537 rs587778046 5:112179623-112179623 5:112843926-112843926
2 APC NM_000038.6(APC):c.4440G>C (p.Gln1480His)SNV Uncertain significance 482375 rs876659881 5:112175731-112175731 5:112840034-112840034
3 APC NM_000038.6(APC):c.8461G>A (p.Asp2821Asn)SNV Uncertain significance 559959 rs1554089164 5:112179752-112179752 5:112844055-112844055

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 TP53 KRAS FGFR2 APC
2 10.87 TP53 KRAS IDH2 IDH1 FGFR2
3
Show member pathways
10.07 IDH2 IDH1

GO Terms for Intrahepatic Cholangiocarcinoma

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP metabolic process GO:0006739 9.16 IDH2 IDH1
2 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
3 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
2 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....